Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Newlight Technologies is a U.S.-based biotechnology and advanced materials company that uses microorganisms to convert methane and carbon dioxide into a biomaterial called AirCarbon. The company positions AirCarbon as a carbon-negative, ocean-degradable polyhydroxybutyrate material that can replace fossil-fuel-based plastics in products such as foodware, textiles, and durable goods. Newlight appears to be a commercial-stage industrial biotech company rather than a therapeutic life sciences or healthcare company. Its core business is platform-based biomaterial production and downstream product commercialization, supported by fermentation and materials manufacturing capabilities. The company has raised private financing and operates production facilities in Southern California.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Newlight Technologies.